Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rasagiline: a guide to its use in Parkinson's disease.

Literature DB >> 22834567

Rasagiline: a guide to its use in Parkinson's disease.

Gillian M Keating¹, Katherine A Lyseng-Williamson, Sheridan M Hoy.

Abstract

Oral rasagiline (Azilect®) as monotherapy or as an adjunct to levodopa provides a useful option in the symptomatic treatment of adult patients with Parkinson's disease. In patients with early Parkinson's disease, monotherapy with rasagiline 1 mg/day improved symptoms of the disease relative to placebo. As adjunctive therapy to levodopa in patients with advanced Parkinson's disease, rasagiline 0.5 or 1 mg/day significantly reduces the total daily 'off' time. Rasagiline is generally well tolerated when administered as monotherapy or as adjunctive therapy.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2012 PMID： 22834567 DOI： 10.2165/11207570-000000000-00000

Source DB: PubMed Journal: CNS Drugs ISSN： 1172-7047 Impact factor: 5.749

13 in total

1. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Authors:
Journal: Arch Neurol Date: 2002-12

Review 2. Alternatives to levodopa in the initial treatment of early Parkinson's disease.

Authors: Andrew Lees
Journal: Drugs Aging Date: 2005 Impact factor: 3.923

3. Safety of rasagiline in elderly patients with Parkinson disease.

Authors: C G Goetz; S R Schwid; S W Eberly; D Oakes; I Shoulson
Journal: Neurology Date: 2006-05-09 Impact factor: 9.910

Review 4. Parkinson's disease.

Authors: C E Clarke
Journal: BMJ Date: 2007-09-01

5. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

Authors:
Journal: Arch Neurol Date: 2005-02

6. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.

Authors: E Tolosa; M B Stern
Journal: Eur J Neurol Date: 2011-08-05 Impact factor: 6.089

7. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

Authors: O Rascol; D J Brooks; E Melamed; W Oertel; W Poewe; F Stocchi; E Tolosa
Journal: Lancet Date: 2005 Mar 12-18 Impact factor: 79.321

Rasagiline: a guide to its use in Parkinson's disease.

1. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Review 2. Alternatives to levodopa in the initial treatment of early Parkinson's disease.

3. Safety of rasagiline in elderly patients with Parkinson disease.

Review 4. Parkinson's disease.

5. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

6. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.

7. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

8. Rasagiline improves quality of life in patients with early Parkinson's disease.

9. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.

Review 10. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations.

1. Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.